Recent Updates
Recently added Catalysts
SCYX

SCYNEXIS, Inc. to Present at Upcoming Investor Conferences

Key Takeaway: JERSEY CITY, N.J., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the following upcoming investor conferences: The Baird Global Healthcare Conference at the New York Palace Hotel on Wednesd

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+56%
120-day peak, hindsight
Typical move
12.1%
average across 3 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
Ibrexafungerp
Phase 3 · Vulvovaginal Candidiasis

Full Press Release Details

JERSEY CITY, N.J., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the following upcoming investor conferences:
The Baird Global Healthcare Conference at the New York Palace Hotel on Wednesday, September 7, 2016 at 4:20 p.m. ET.
The 23rd Annual NewsMakers in the Biotech Industry Investment Conference at the Millennium Broadway in New York on Friday, September 9, 2016 at 9:30 a.m. ET.
The Aegis Growth Conference at the Wynn Las Vegas on Thursday, September 22, 2016 at 9:00 a.m. PT.
Live webcasts of the presentations will be available on the investors section of the Company's website: www.SCYNEXIS.com. Replays of each presentation will be available approximately two hours after each event and will be available for two weeks following the presentations.
SCYNEXIS is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and IV drug for the treatment of serious and life-threatening invasive fungal infections. For more information, visit www.SCYNEXIS.com.
Last updated: Aug 31, 2016